Research Article
Volume 7 Issue 9 - 2020
Screening of the Patients with Autoimmune Thyroid Disease (AITD) and Type 1 Diabetes Mellitus (DM1) for Atrophic Gastritis (AG) by Serological Biomarker Testing (GastroPanel®)
Olli-Pekka Koivurova1, Olavi Ukkola2, Minna Koivikko2, Tapani Ebeling2, Iina Yliaska2, Ritva Koskela2, Timo Blomster2, Antti Ala-Rämi2, Olli Kettunen2, Tuomo J Karttunen3, Markus Mäkinen3,4, Jukka Ronkainen5,6 and Kari Syrjänen7,8*
1Departmernt of Endoscopy, Terveystalo Medical Center, Oulu, Finland
2Research Unit of Internal Medicine, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Finland
3Cancer and Translational Medicine Research Unit, University of Oulu, Finland
4Department of Pathology, Oulu University Hospital, Finland
5Center for Life Course Health Research, University of Oulu, Finland
6Primary Health Care Center, Tornio, Finland
7Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil
8SMW Consultants Ltd., Kaarina, Finland
*Corresponding Author: Kari Syrjänen, Professor, SMW Consultants Ltd., Kaarina, Finland.
Received: July 09, 2020; Published: August 29, 2020


Background: The high prevalence (10 - 30%) of autoimmune atrophic gastritis (AAG/AG) in patients with autoimmune thyroid disease (AITD) or type 1 diabetes mellitus (DM1) advocates a screening of these patients by gastroscopy. An alternative to invasive gastroscopy is offered by a non-invasive serological biomarker test; GastroPanel® (Biohit Oyj, Helsinki, Finland).

Objective: To establish the prevalence of AAG/AG in AITD- and DM1 patients by the new-generation GastroPanel® test in a clinical validation study.

Material and Methods: A cohort of 244 patients (207 with AITD and 37 with DM1) was enrolled at the Outpatient Department of Internal Medicine, Oulu University Hospital (OUH, Oulu, Finland). A written consent was obtained from all patients, and the study was approved by the joint Ethical Committee of OUH/Oulu University (Dno 28/2017). All patients underwent GastroPanel® examination and those with AG/AAG biomarker profile were referred for gastroscopy and biopsy confirmation (reference test).

Results: Of the 244 patients, biopsy-confirmed AG was found in 12.0% (25/207) of the AITD- and in 10.8% (4/37) of the DM1 patients. The adjusted overall agreement between GastroPanel® and the USS classification was 73.3% (95%CI 60.4 - 86.2%), and the adjusted weighted kappa: kw = 0.881 (95%CI 0.783 - 0.935). In ROC analysis for AGC2+ (moderate/severe AGC) endpoint, the ROC curves have AUC = 0.939 (95%CI 0.870 - 1.000) and AUC = 0.945 (95%CI 0.879 - 1.000) for PGI and PGI/PGII, respectively.

Conclusion: AG/AAG is far more prevalent among the AITD- and DM1 patients as compared with general population. The new generation GastroPanel® is an ideal test for non-invasive screening of these patients for early diagnosis of AG/AAG.

Keywords: Autoimmune Thyroid Disease (AITD); Type I Diabetes Mellitus (DM1); Autoimmune Atrophic Gastritis (AAG); Atrophic Gastritis (AG); Serological Biomarker Panel; GastroPanel; Non-Invasive; Helicobacter pylori; Pepsinogen I; Pepsinogen II; Gastrin-17; Pernicious Anemia; Parietal Cell Antibody


  1. Whittingham S and Mackay IR. “Pernicious anemia and gastric atrophy”. In: Rose NR, Mackay IR, editions. The autoimmune diseases. New York: Academic Press (1985): 243-266.
  2. Jacobson DL., et al. “Epidemiology and estimated population burden of selected autoimmune diseases in the United States”. Clinical Immunology and Immunopathology 84 (1997): 223-243.
  3. Carmel R. “Prevalence of undiagnosed pernicious anemia in the elderly”. Archives of Internal Medicine 156 (1996): 1097-1100.
  4. Centanni M., et al. “Atrophic body gastritis in patients with autoimmune thyroid disease. An underdiagnosed association”. Archives of Internal Medicine 159 (1999): 1726-1730.
  5. Irvine WJ., et al. “Thyroid and gastric autoimmunity in patients with diabetes mellitus”. Lancet 2 (1970): 163-168.
  6. Riley WJ., et al. “Predictive value of gastric parietal cell autoantibodies as a marker for gastric and hematologic abnormalities associated with insulin dependent diabetes”. Diabetes 31 (1982): 1051-1055.
  7. De Block CEM., et al. “Autoimmune Gastritis in Type 1 Diabetes: A Clinically Oriented Review”. The Journal of Clinical Endocrinology and Metabolism 93 (2008): 363-371.
  8. Strickland RG and Mackay I. “A reappraisal of the nature and significance of chronic atrophic gastritis”. American Journal of Digestive Diseases 18 (1973): 426-440.
  9. Marignani M., et al. “High prevalence of atrophic body gastritis in patients with unexplained microcytic and macrocytic anemia”. The American Journal of Gastroenterology 94 (1999): 766-772.
  10. De Block CE., et al. “Soluble transferrin receptor level: a new marker of iron deficiency anemia, a common manifestation of gastric autoimmunity in type 1 diabetes”. Diabetes Care 23 (2000): 1384-1388.
  11. Collins AB and Pawlak R. “Prevalence of vitamin B-12 deficiency among patients with thyroid dysfunction”. Asia Pacific Journal of Clinical Nutrition 25 (2016): 221-226. 
  12. Kokkola A., et al. “The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia: a prospective follow-up study”. Scandinavian Journal of Gastroenterology 33 (1998): 88-92.
  13. Addison T. “Anaemia: disease of the suprarenal capsules”. London Medical Gazette 8 (1998): 517-518.
  14. Flint A. “A clinical lecture on anaemia, delivered at the Long Island College Hospital”. American Medical Times 1 (1860): 181-186.
  15. Castle WB. “Development of knowledge concerning the gastric intrinsic factor and its relation to pernicious anemia”. The New England Journal of Medicine 249 (1953): 603-614.
  16. Schwartz M. “Intrinsic factor antibody in serum from patients with pernicious anaemia”. Lancet 2 (1960): 1263-1267.
  17. Irvine WJ., et al. “Immunological relationship between pernicious anemia and thyroid disease”. British Medical Journal 2 (1962): 454-456. 
  18. Irvine W. “Immunologic aspects of pernicious anemia”. The New England Journal of Medicine 273 (1965): 432-438.
  19. Maclaren NK and Riley WJ. “Thyroid, gastric, and adrenal autoimmunities associated with insulin-dependent diabetes mellitus”. Diabetes Care 8.1 (1985): 34-38.
  20. Betterle C., et al. “Clinical and subclinical organ-specific autoimmune manifestations in type 1 (insulin-dependent) diabetic patients and their first-degree relatives”. Diabetologia 26 (1984): 431-436. 
  21. Landin-Olsson M., et al. “Islet cell and thyrogastric antibodies in 633 consecutive 15- to 34-yr-old patients in the diabetes incidence study in Sweden”. Diabetes 41 (1992): 1022-1027. 
  22. Betterle C., et al. “Complement-fixing gastric parietal cell autoantibodies. A good marker for the identification of type A chronic atrophic gastritis”. Autoimmunity 1 (1988): 267-274.
  23. Oksanen A., et al. “Atrophic gastritis and Helicobacter pylori infection in outpatients referred for gastroscopy”. Gut 46 (2000): 460-463. 
  24. Cruchaud A and Juditz E. “An analysis of gastric parietal cell antibodies and thyroid cell antibodies in patients with pernicious anaemia and thyroid disorders”. Clinical and Experimental Immunology 3.8 (1968): 771-781. 
  25. Ungar B., et al. “Intrinsic factor antibody, parietal-cell antibody, and latent pernicious anaemia in diabetes mellitus”. Lancet 2 (1968): 415-417.
  26. De Block CE., et al.b-cell, thyroid, gastric, adrenal and coeliac autoimmunity and HLA-DQ types in type 1 diabetes”. Clinical and Experimental Immunology 126 (2001): 236-241. 
  27. Tozzoli R., et al. “Autoantibodies to parietal cells as predictors of atrophic body gastritis: a five-year prospective study in patients with autoimmune thyroid diseases”. Autoimmunity Reviews 10.2 (2010): 80-83. 
  28. Venerito M., et al. “Autoimmune gastritis in autoimmune thyroid disease”. Alimentary Pharmacology and Therapeutics 41.7 (2015): 686-693. 
  29. Castoro C., et al. “Association of autoimmune thyroid diseases, chronic atrophic gastritis and gastric carcinoid: experience from a single institution”. Journal of Endocrinological Investigation 39 (2016): 779. 
  30. Lahner E., et al. “Occurrence and risk factors for autoimmune thyroid disease in patients with atrophic body gastritis”. The American Journal of Medicine 121 (2008): 136-141.
  31. D’Annunzio G., et al. “Autoimmune disorders associated to type 1 diabetes mellitus in children and adolescents, Chapter 1”. In: Autoimmune Disorders - Current Concepts and Advances from Bedside to Mechanistic Insights, Fang-Ping Huang (Edition.) (2011):1-26. 
  32. Annibale B., et al. “The stomach and iron deficiency anaemia: a forgotten link”. Digestive and Liver Disease 35 (2003): 288-295.
  33. Toh BH and Alderuccio F. “Pernicious anaemia”. Autoimmunity 37 (2004): 357-361.
  34. Irvine WJ., et al. “Natural history of autoimmune achlorhydric atrophic gastritis”. Lancet 2 (1974): 482-485.
  35. Armbrecht U., et al. “Development of gastric dysplasia in pernicious anaemia: a clinical and endoscopic follow-up study of 80 patients”. Gut 31:1105-1109.
  36. Borch K., et al. “Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia”. Gastroenterology 88 (1985): 638-648.
  37. Sjöblom SM., et al. “Gastroscopic follow-up of pernicious anaemia patients”. Gut 34 (1993): 28-32.
  38. Hsing A., et al. “Pernicious anemia and subsequent cancer: a population-based cohort study”. Cancer 71 (1993): 745-750. 
  39. Brinton L., et al. “Cancer risk following pernicious anaemia”. British Journal of Cancer 59 (1989): 810-813. 
  40. Carpenter C and Patalas E. “Case records of the Massachusetts General Hospital (Case 40-2000): a 38-year-old woman with gastric adenocarcinoma”. The New England Journal of Medicine 343 (2000): 1951-1958.
  41. Appelmelk B., et al. “Bugs on trial: the case of Helicobacter pylori and autoimmunity”. Immunology Today 19 (1998): 296-299.
  42. Amedei A., et al. “Molecular mimicry between Helicobacter pylori antigens and H+, K+-adenosine triphosphatase in human gastric autoimmunity”. Journal of Experimental Medicine 198 (2003): 1147-1156.
  43. Van Driel IR., et al. “Shaping the T cell repertoire to a bona fide autoantigen: lessons from autoimmune gastritis”. Current Opinion in Immunology 17 (2005): 570-576.
  44. D’Elios MM., et al. “Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry”. Trends in Molecular Medicine 10 (2004): 316-323. 
  45. Sipponen P., et al. “Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data”. International Journal of Cancer 35 (1985): 173-177.
  46. Correa P., et al. “Gastric precancerous process in a high risk population: cohort follow-up”. Cancer Research 50 (1990): 4737-4740.
  47. Filipe MI., et al. “Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia”. The International Journal of Cancer 57 (1994): 324-329.
  48. Ohata H., et al. “Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer”. The International Journal of Cancer 109 (2004): 138-143.
  49. Correa P. “A human model of gastric carcinogenesis”. Cancer Research 48 (1988): 3554-3560.
  50. Correa P. “The epidemiology of gastric cancer”. World Journal of Surgery 15 (1991): 228-234.
  51. Correa P. “Human gastric carcinogenesis: a multistep and multifactorial process -First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention”. Cancer Research 52 (1992): 6735-6740. 
  52. Malfertheiner P., et al. “European Helicobacter Study Group. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report”. Gut 61 (2012): 646-664.
  53. Uemura N., et al. “Helicobacter pylori infection and the development of gastric cancer”. The New England Journal of Medicine 345 (2001): 829-832.
  54. Weck MN., et al. “Epidemiology of chronic atrophic gastritis: population-based study among 9444 older adults from Germany”. Alimentary Pharmacology and Therapeutics 26 (2007): 879-887.
  55. Lomba-Viana R., et al. “Serum pepsinogen test for early detection of gastric cancer in a European country”. European Journal of Gastroenterology and Hepatology 24 (2012): 37-41.
  56. Bornschein J., et al. “Serological assessment of gastric mucosal atrophy in gastric cancer”. BMC Gastroenterology 12 (2012): 10. 
  57. Valle J., et al. “Longterm course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study”. Scandinavian Journal of Gastroenterology 31 (1996): 546-550.
  58. Germaná B., et al. “Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacterpylori antibodies in the management of dyspeptic patients in primary care”. Digestive and Liver Disease 37 (2005): 501-508.
  59. Miki K., et al. “Serum pepsinogens as a screening test of extensive chronic gastritis”. The Journal of Gastroenterology 22 (1987): 133-141.
  60. Samloff IM., et al. “Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia”. Gastroenterology 83 (1982): 204-209.
  61. Korstanje A., et al. “The serological gastric biopsy: a non-endoscopical diagnostic approach in management of the dyspeptic patient: significance for primary care based on a survey of the literature”. Scandinavian Journal of Gastroenterology 236 (2002): 22-26.
  62. Oksanen A., et al. “Evaluation of blood tests to normal gastric mucosa”. Scandinavian Journal of Gastroenterology 35 (2000): 791-795.
  63. Varis K., et al. “Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia”. Scandinavian Journal of Gastroenterology 35 (2000): 950-956.
  64. Miki K. “Gastric cancer screening using the serum pepsinogen test method”. Gastric Cancer 9 (2006): 245-253.
  65. Agréus L., et al. “Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers”. Scandinavian Journal of Gastroenterology 47 (2012): 136-147.
  66. Aro P., et al. “Validation of the translation and cross-cultural adaptation into Finnish of the Abdominal Symptom Questionnaire, the Hospital Anxiety and Depression Scale and the Complaint Score Questionnaire”. Scandinavian Journal of Gastroenterology 39 (2004): 1201-1208.
  67. Syrjänen K., et al. “GastroPanel® Biomarker Panel: The most comprehensive test for Helicobacter pylori infection and its clinical sequelae. A critical review”. Anticancer Research 39 (2019): 1091-1104. 
  68. Syrjänen K. “A Panel of serum biomarkers (GastroPanel®) in non-invasive diagnosis of atrophic gastritis. Systematic review and meta-analysis”. Anticancer Research 36 (2016): 5133-5144.
  69. Dixon MF., et al. “Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994”. The American Journal of Surgical Pathology 20 (1996): 1161-1181.
  70. Seed PT and Tobias A. “Summary statistics for diagnostic tests”. Stata Techn Bull 59 (2001): 9-12.
  71. Ma JY., et al. “Positive correlation between H,K-adenosine triphosphatase autoantibodies and Helicobacter pylori antibodies in patients with pernicious anemia”. Scandinavian Journal of Gastroenterology 29 (1994): 961-965.
  72. Uibo R., et al. “Association of Helicobacter pylori and gastric autoimmunity: a population-based study”. FEMS Immunology and Medical Microbiology 11 (1995): 65-68.
  73. Zagari RM., et al. “Systematic review with meta-analysis: Diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis”. Alimentary Pharmacology and Therapeutics 46 (2017): 1-11.  
  74. Syrjänen KJ., et al. “Accuracy of GastroPanel testing in detection of atrophic gastritis”. European Journal of Gastroenterology and Hepatology 27 (2015): 102-104.  
  75. Reid M., et al. “Academic calculations versus clinical judgments: practicing physicians’ use of quantitative measures of test accuracy”. The American Journal of Medicine 104 (1998): 374-380.
  76. Van den Ende J., et al. “The trouble with likelihood ratios”. Lancet 366 (2005): 548.
  77. Fagan TJ. “Letter: nomogram for Bayes theorem”. The New England Journal of Medicine 293 (1975): 257.
  78. Straus S., et al. “Evidence-based medicine: how to practice and teach it”. 4th edition. Edinburgh: Churchill Livingstone (2011).
Citation: Kari Syrjänen., et al. “Screening of the Patients with Autoimmune Thyroid Disease (AITD) and Type 1 Diabetes Mellitus (DM1) for Atrophic Gastritis (AG) by Serological Biomarker Testing (GastroPanel®)”. EC Gastroenterology and Digestive System 7.9 (2020): 181-195.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

January Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the January issue of respective journals and can be viewed in the current issue pages.

Submission Deadline for January Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the January issue of respective journals. Submissions are accepted on/before January 26, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to